Chen Zhenfeng, Xing Shasha, Huang Yingzhuan, Zeng Qifeng, Xu Donghan, He Qiumei, Qin Huangguan, Luo Xiaofan, Li Renfeng
Guangxi university of Traditional Chinese Medicine.
Ruikang Hospital affiliated to Guangxi University of Chinese Medicine, Nanning, Guangxi Province.
Medicine (Baltimore). 2020 Oct 16;99(42):e22737. doi: 10.1097/MD.0000000000022737.
Allergic rhinitis (AR), characterized by nasal itching, sneezing, and congestion, is a common disorder of nose. In the United States, AR affects 10% to 20% of adults. The negative impact of the high prevalence of AR has caused a great economic burdens worldwide. Modern Western Medicine mainly treats AR with antihistamine drugs, glucocorticoids, allergic immunotherapy (AIT), but it seriously affects patients compliance because of its long course of treatment, high medical costs and side effect. And now, as an important mean of treating AR, acupoint injection has been widely used in clinics, and has achieved significant efficacy.
The following databases will be searched for relevant information before July 2020: PubMed, Embase, Cochrane Library, Web of Science, and CNKI.
scores of Rhinitis Quality of Life (RQLQ), Rhinitis Total Symptom Scores (RTSS). Secondary results: levels of antigen-specific serum immunoglobulin E (IgE), total effective rate, adverse event. Data will be collected independently by 2 researchers, and the risk of bias in meta-analysis will be evaluated according to "Cochrane Handbook for Systematic Reviews of Interventions". All data analysis will be conducted using Review Manager V.5.3. and Stata V.12.0.
The curative effect and safety of acupoint injection treatment for AR patients will be evaluated systematically.
The systematic review of this study will summarize the currently published evidence of acupoint injection treatment for AR to further guide its promotion and application.
The private information from individuals will not be published. This systematic review also will not involve endangering participant rights. Ethical approval is not required. The results may be published in a peer-reviewed journal or disseminated in relevant conferences.Open Science Framework (OSF) registration number: https://osf.io/fa9dq.
变应性鼻炎（AR）以鼻痒、打喷嚏和鼻塞为特征，是一种常见的鼻部疾病。在美国，AR影响10%至20%的成年人。AR高患病率的负面影响在全球范围内造成了巨大的经济负担。现代西医主要用抗组胺药、糖皮质激素、变应性免疫疗法（AIT）治疗AR，但由于其疗程长、医疗成本高和副作用大，严重影响患者的依从性。目前，穴位注射作为治疗AR的一种重要手段，已在临床上广泛应用，并取得了显著疗效。
在2020年7月之前，将检索以下数据库以获取相关信息：PubMed、Embase、Cochrane图书馆、科学网和中国知网。
鼻炎生活质量（RQLQ）评分、鼻炎总症状评分（RTSS）。次要结果：抗原特异性血清免疫球蛋白E（IgE）水平、总有效率、不良事件。数据将由2名研究人员独立收集，荟萃分析中的偏倚风险将根据《Cochrane干预措施系统评价手册》进行评估。所有数据分析将使用Review Manager V.5.3和Stata V.12.0进行。
将系统评价穴位注射治疗AR患者的疗效和安全性。
本研究的系统评价将总结目前已发表的穴位注射治疗AR的证据，以进一步指导其推广和应用。
不会公布个人隐私信息。本系统评价也不会涉及危及参与者权利的问题。无需伦理批准。结果可能发表在同行评审期刊上或在相关会议上传播。开放科学框架（OSF）注册号：https://osf.io/fa9dq 。
